Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2020

View Archived Issues

Autophagy linked to neurotransmission

A promising multitarget antipsychotic among piperidine-amide substituted derivatives

Immuron reports new data on vaccine targeting Campylobacter and ETEC

Arcturus reports interim data from phase I/II study of COVID-19 vaccine candidate ARCT-021

Gilead Sciences patents HIV protease inhibitors

Aligos Therapeutics divulges new compounds for hepatitis

Vivace Therapeutics synthesizes YAP1/TEAD interaction inhibitors

LIfT BioSciences reports in vivo data on N-LIfT for pancreatic cancer

GBiotech Sarl presents new FFAR1 agonists

Chinese researchers discover EpCAM-targeting antibodies

hAd5-COVID-19 stimulates memory T-cell recall in previously infected COVID-19 patients

First patient dosed in phase I study of NTLA-2001 in hATTR-PN

Researchers develop a new Ptpn14-knockout murine model of HHT

European Commission approves Calquence for the treatment of CLL

Study shows how mutant KRAS initiates pancreatic cancer

Preclinical characterization of [99mTc]Tc-TECANT-1

[125I]PIB-Ec1 as promising tracer for imaging EpCAM expression in ovarian cancer

Phase III NAVIGATOR study of tezepelumab in severe asthma meets primary endpoint

GlaxoSmithKline's RSVPreF3 candidate vaccine shows promising clinical results

Arena reports topline phase IIb results with etrasimod in atopic dermatitis

New phase Ib/IIa trial examines Immunophotonics' IP-001 in thermally ablated solid tumors

FDA issues EUA for Lilly's bamlanivimab to treat recently diagnosed COVID-19

Phase I/II data with PKU gene therapy HMI-102 show marked reductions in Phe at two doses

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

FDA approves Totect to treat cardiomyopathy in women receiving doxorubicin for breast cancer

Sorrento files IND for STI-2020 for treatment of COVID-19

FDA issues complete response letter for SPN-812 for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.